INS and type 2 diabetes mellitus: Considerable increases are expected for antidiabetic agents excluding insulin (13% in 2010 and 9% in 2011) due to the increased prevalence of type 2 diabetes [17], new National Guidelines suggesting stricter targets for HbA1c, and the introduction of several new drugs (the GLP-I agonists exenatide and liraglutide, as well as the DPP-4 inhibitors sitagliptin, vildagliptin and saxagliptin) [18].